ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleural mesothelioma (MPM) may improve treatment outcome...

Full description

Bibliographic Details
Main Authors: Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Sylvia Vetrhus, Alex Martinez-Marti, Santiago Viteri, Alejandro Navarro, Jon Zugazagoitia, Santiago Ponce, Mercedes Herrera-Juarez, Mathieu Lederlin, Thomas Birkballe Hansen
Format: Article
Language:English
Published: BMJ Publishing Group 2023-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/9/e007552.full

Internet

https://jitc.bmj.com/content/11/9/e007552.full

Similar Items